Eligo Biosciences

Eligo Bioscience is a young biotech that develops smart antibiotics for microbiome precision-editing.

Eligo Bioscience develops Eligobiotics, which are antimicrobials that programmed to target bacteria based on their genome. 

Eligo Bioscience was founded in 2014 and is based in Paris, Ile-de-France, France.

 

Eligo Bioscience's Eligobiotics are protein-based nanodelivery vectors that contain a synthetic circuit encoding for a programmable RNA-guided nuclease.

 

Eligo Bioscience is backed by prominent investors such as Khosla Ventures, Seventure Partners, AGORANOV, & Worldwide Innovation Challenge.

 

 

  • Year founded: 2014
  • Funding Info: $22.9M in 4 funding rounds (Last funding type: Series A)
  • Yearly Revenue: $1M - $2M (2018)
  • Employee Size: 11-50
  • Business Valuation: NA
  • City/Town: Paris
  • State: Ile-de-France
  • Country: France
Related businesses